(Q35199072)

7 August 2017

Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile (English)

1 reference

7 August 2017

Clostridium difficile

0 references

author name string

Farah Babakhani

1

1 reference

7 August 2017

Abraham Gomez

2

1 reference

7 August 2017

Nikki Robert

3

1 reference

7 August 2017

Pamela Sears

4

1 reference

7 August 2017

24 February 2011

1 reference

Journal of Medical Microbiology

7 August 2017

1 reference

7 August 2017

60

1 reference

7 August 2017

Pt 8

1 reference

7 August 2017

1213-1217

1 reference

Fidaxomicin (OPT-80) for the treatment of Clostridium difficile infection

7 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3167880

Clostridium difficile infection: new developments in epidemiology and pathogenesis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3167880

Review of current literature on the economic burden of Clostridium difficile infection

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3167880

OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3167880

Lipiarmycin targets RNA polymerase and has good activity against multidrug-resistant strains of Mycobacterium tuberculosis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3167880

Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3167880

In vitro activities of OPT-80 and comparator drugs against intestinal bacteria

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3167880

Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3167880

Lipiarmycin: An antibiotic inhibiting nucleic acid polymerases

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3167880

Initiation of transcription in vitro is inhibited by lipiarmycin

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3167880

A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3167880

In vitro activity of OPT-80 against Clostridium difficile

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3167880

Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial

26 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21349983

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Pharmacodynamic studies of vancomycin, metronidazole and fusidic acid against Clostridium difficile

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21349983

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1099/JMM.0.029470-0

1 reference

7 August 2017

1 reference

7 August 2017

1 reference